Moderna Says CCP Virus Vaccine Nearly 95 Percent Effective
A vaccine candidate jointly developed by Moderna and the National Institutes of Health (NIH) has been shown in early results to be 94.5 percent effective.

“This publication is an exact copy of author’s original, it is intended to spread out information regarding COVID-19 and not necessarily reflects the PREMIERE SCIENTIFIC or its employees opinion”

BY
TOM OZIMEK November 16, 2020 in Epoch Times




Biotech company Moderna said in a statement on Nov. 16 that an analysis of its clinical trial by an

independent data and safety monitoring board shows that its experimental vaccine is highly

effective at preventing infection by the CCP virus.

NIH said in a separate release that “the findings are statistically significant, meaning they are likely

not due to chance. This interim review of the data suggests that the vaccine is safe and effective

at preventing symptomatic COVID-19 in adults.”

The vaccine trial enrolled more than 30,000 participants in the United States, with half of the study

subjects receiving two doses of the vaccine 28 days apart and the other half receiving two shots

of a placebo.

The vaccine combines Moderna’s messenger RNA delivery platform with the stabilized SARSCoV-

2 spike immunogen developed by scientists at the National Institute of Allergy and Infectious

Diseases (NIAID), which is part of NIH.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” said Stéphane

Bancel, chief executive officer of Moderna, in a statement.

“This positive interim analysis from our Phase 3 study has given us the first clinical validation that

our vaccine can prevent COVID-19 disease, including severe disease,” Bancel said. “This

milestone is only possible because of the hard work and sacrifices of so many.”

A subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by

Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in

Seattle, Wash., on March 16, 2020. (Ted S. Warren/AP Photo)

The study is being done in collaboration with NIH, NIAID, and the Biomedical Advanced Research

and Development Authority (BARDA), which is part of the Department of Health and Human

Services.

“I want to thank our partners at BARDA and Operation Warp Speed who have been instrumental

to accelerating our progress to this point,” Bancel said, referring to the Trump administration’s

effort to accelerate the development, manufacturing, and distribution of a COVID-19 vaccine,

therapeutics, and diagnostics.

Moderna said it plans to file an application for emergency use authorization of its vaccine with the

Food and Drug Administration sometime “in the coming weeks.”

“We look forward to the next milestones of submitting for an EUA in the U.S., and regulatory filings

in countries around the world, while we continue to collect data on the safety and efficacy of the

vaccine in the COVE study,” Bancel said. “We remain committed to and focused on doing our part

to help end the COVID-19 pandemic.”

The company said it expects to be able to ship around 20 million doses of its vaccine in the United

States by the end of 2020 and that next year, it expects to be able to make between 500 million

and 1 billion doses available around the world.

Together with Pfizer’s vaccine, which appears to be more than 90 percent effective, the United

States could have two vaccines authorized for emergency use in December, with as many as 60

million doses of vaccine available this year.

A key advantage of Moderna’s vaccine is that, unlike Pfizer’s, it doesn’t need to be stored at very

low temperatures, making it easier to distribute.

Virus cases topped 11 million in the United States over the weekend, with 1 million of them

recorded in just the past week.